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Abstract: Dupuytren’s disease is a common condition. Its management has gradually evolved but still remains a source of 
much controversy. Recently there has been a resurgence in the popularity of percutaneous needle fasciotomy. It is a 
simple method that uses a hypodermic needle as a scalpel blade. It is usually performed in the out-patient setting under 
local anaesthesia without a tourniquet. It has few complications and allows almost immediate return to work with few 
restrictions. 
It can provide complete deformity correction and may offer a long-term solution in selected patients. It is also useful in 
converting advanced contractures into milder deformities, allowing a second stage digito-palmar fasciectomy to be more 
successful. Recurrence is earlier than with more formal and invasive techniques but the procedure can be repeated and 
does not preclude the patient from further surgery. 
This article reviews the technique and assesses the efficacy and outcomes of published data. 
Keywords: Dupuytren’s disease, percutaneous needle fasciotomy. 
INTRODUCTION 
  Dupuytren’s disease is a chronic fibrosing disorder 
consisting of pathologic production and deposition of 
collagen in the palmar fascia of the hand. Consequently 
nodules and cords develop causing a potentially debilitating 
flexion contracture of the metacarpophalangeal (MCP) joint, 
proximal interphalangeal (PIP) joint and even the distal 
interphalangeal (DIP) joint. Dupuytren’s contracture is most 
commonly observed in persons of Northern European 
descent and affects 4-6% of Caucasians worldwide [1]. The 
ring finger is most commonly involved, followed by the little 
finger and then the middle finger. The index finger and the 
thumb are typically spared. 
  The cause of Dupuytren’s disease is largely unknown but 
a family history is often present. Males are three times as 
likely to develop the disease and are more likely to have a 
more severe form [2]. Male predominance may be related to 
expression of androgen receptors in the palmar fascia [3]. 
Additional risk factors include family history, anti-epileptics, 
diabetes and hyperlipidaemia. 
  Dupuytren’s disease is common and historically has been 
surrounded by much controversy. Indeed its origins in the 
medical literature have been widely debated. The disease 
bears its name after the French surgeon, Baron Guillaume 
Dupuytren, who meticulously presented the clinical and 
anatomic features in 1831. Prior to that an Englishman, 
Henry Cline in 1777, and his successor, Astley Cooper in 
1822, had previously described, published and treated the 
contractures. It seems, however, they were all beaten to it by 
Felix Plater, of Basel in Switzerland, who in 1614 described  
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the condition in a mason with flexion contractures of his ring 
and little fingers, and identified the palmar aponeurosis as 
the source of pathology [4]. 
  Traditional management has involved observation, 
fasciotomy, limited fasciectomy, total fasciectomy and 
dermo-fasciectomy. Like most surgical techniques, these 
have evolved and although recurrence rates and 
complications have been reduced, their occurrence is not 
insignificant. This has shifted the emphasis towards less 
invasive techniques and, in particular, percutaneous needle 
fasciotomy. 
  Percutaneous needle fasciotomy is not a new technique 
and was first performed with a bistoury (a long narrow 
bladed knife) in England by Henry Cline in 1787. It was re-
introduced on the continent in the early 1970s and 
popularised by the French rheumatologists Lermusiaux and 
Debeyre [5], and later Badois [6]. In the UK it has only 
recently gained popularity. 
TECHNIQUE 
Indications and Principles 
  The procedure aims to divide the diseased cord by the 
use of the bevel of the needle and thereby restore extension 
of the PIP and MCP joints. Best results are seen in early 
disease and with more proximal (MCP joint) involvement. A 
palpable cord must be present with adequate overlying skin. 
Where full correction is unlikely to be achieved with needle 
fasciotomy (for example in combined MCP and PIP joint 
contractures), it remains a useful first stage procedure 
allowing the skin to stretch out before a formal second stage 
digito-palmar fasciectomy. 
  It is usually performed in the out-patient setting without 
the use of a tourniquet. Contraindications include infiltrating 
disease, inaccessible multiple cords, post-surgical digital 84    The Open Orthopaedics Journal, 2012, Volume 6  Donaldson and Goddard 
recurrences, rapid recurrences in young patients 
(Dupuytren’s diathesis), and severe digital disease causing 
PIP joint stiffness. 
Surgical Anatomy 
  Portals are best planned in areas where the skin is soft, 
non-adherent and where the cord is a discrete linear 
structure. If more than one portal is needed, they are spaced 
at least 5mm apart. Fasciotomies at the palmar level are safe 
- the neurovascular structures run deep to the subcutaneous 
fat. Distal to the MCP joint care is needed as the anatomy 
becomes distorted and risk of neurovascular injury is higher. 
Only midline and prevascular cords, which are extended 
under the skin, are accessible. 
  To avoid tendon damage the patient is intermittently 
asked to actively flex and extend the PIP and DIP joints to 
demonstrate the presence or absence of needle motion with 
active tendon excursion. If the needle moves with the finger 
it suggests inadvertent entry into the flexor tendon sheath 
and the needle should be re-positioned. The procedure and 
post-operative protocol are explained to the patient, 
including the importance of reporting any finger paraesthesia 
or numbness and avoiding any sudden movements. 
Preparation 
  The patient washes their hands with soap and water. The 
skin is then cleaned with alcoholic disinfectant and 1-3mls of 
1% lignocaine are injected using a 29-31 gauge hypodermic 
needle and syringe - an insulin syringe is particularly useful. 
Sterile drapes and gloves are not required. The skin and 
subdermal tissue around the Dupuytren cord of interest are 
infiltrated. It is important to keep the needle in the subdermal 
layer to avoid neurovascular and tendon injury. Cords are 
insensate (neurovascular structures and flexor tendon sheaths 
are not) and this allows inadvertent injury to be avoided. 
Some experts in fact do not use local anaesthetic, as they 
believe it may obscure inadvertent digital nerve damage. The 
patient should be sitting or recumbent to avoid potential 
vasovagal complications. 
Procedure 
  The aim is to provide a transverse fasciotomy deep to the 
skin where the cord is a discrete linear structure. Nodules 
and skin creases should be avoided. Skin creases are 
generally in close proximity to the flexor tendon sheath and 
are also potential sites for skin tears. Nodules have little 
effect on the deformity or its correction. A 23 gauge (blue) 
hypodermic needle is inserted through the skin and the 
dermis. The tip of the needle is placed under the skin 
perpendicular to the cord. A reciprocating motion is used to 
define the extent and surface geometry of the cord. There are 
different ways to divide the cord once the anatomy has been 
defined. The senior author prefers a ‘sawing’ type action 
with the needle at ninety degrees to the cord and using the 
bevel of the needle on the surface and dividing it 
incrementally from superficial to deep. Another option is the 
multiple stab technique, which some authors believe to be 
safer - in that the patient may experience sensory changes if 
the digital nerve is encountered. 
 
  The cords must be held under tension to allow the needle 
to ‘cut’ and to pull the cord up and away from the deeper 
structures. A sensation of resistance should be felt and the 
fascia should feel crisp when cut – this is often audible. 
Passive stretching may be done after each release, which 
pulls the ends of the cord apart and obtains maximal release 
of the contracture. The process may be repeated if necessary, 
from proximal to distal, if there is still cord causing a 
residual contracture. For advanced Dupuytren’s successive 
sessions can be proposed. Some authors advocate the use of 
Doppler examination where there is a possibility of a spiral 
cord in order to avoid neurovascular injury [7]. 
  In addition some authors advocate the use of 
corticosteroid injections at the time of fasciotomy or soon 
after to soften the cord plus or minus any co-existing 
nodules. There is little evidence to suggest performing this 
routinely and is not the senior author’s preferred technique. 
Post-Procedure 
  A simple dressing can be applied to the wound and the 
patient can continue with their normal activities. Physical 
therapy is not usually needed but the patient is advised to 
regularly stretch out their finger. Occasionally a splint may 
be beneficial. If there has been a tear in the skin, strenuous 
gripping or heavy manual labour should be avoided until it 
has healed - similar to the McCash technique. 
Complications 
  Skin tears may occur which may need bandaging until 
they heal. They are more common in and adjacent to flexion 
creases. Other complications include nerve injury and flexor 
tendon injury, which are both rare. 
Clinical Example 
  A 56 year old right hand dominant male with progressive 
Dupuytren’s contracture seen in the out-patients department 
for the first time. His deformity largely involves the MCP 
joint of the little finger. It currently restricting his work as a 
mechanic. 
  Local anaesthetic is injected after consideration of 
appropriate portal placement. A blue hypodermic needle is 
inserted and the bevel and tip are used to divide the cord. 
The patient is monitored continually for fingertip numbness 
(digital nerve injury or contusion) and needle movement 
with active tendon excursion (insertion of the needle into the 
flexor tendon). Complete correction is achieved. The patient 
will be followed up serially to assess for recurrence and if 
necessary the procedure can be repeated. 
  If the cord feels rubbery or is no longer being divided the 
needle can be changed for a fresh one. The patient is 
educated on the likelihood of recurrence (as with all 
Dupuytren’s procedures) and post-operative stretching (see 
Fig. 1a-e). 
DISCUSSION 
  There is a huge amount of literature regarding the 
treatment of Dupuytren’s disease, but few quality studies 
assessing one technique over another. Van Rijssen et al., [8] 
performed a prospective randomised controlled trial   
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Fig. (1). a) The pre-procedure deformity; b) injection of local anaesthetic; c) needle placement; d) needle fasciotomy with tension on the 
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comparing percutaneous needle fasciotomy and limited open 
fasciectomy in 117 hands. For Tubiana stages 1 and 2 (see 
Table  1) percutaneous fasciotomy was equal to limited 
fasciectomy in efficacy. For Tubiana stage 3 and 4 disease 
limited fasciectomy was superior. Limited fasciectomy was, 
however, associated with a 5% major complication rate 
(compared to zero major complications in the needle 
fasciotomy group). In addition pain scores and satisfaction 
with hand function were consistently better in the 
percutaneous fasciotomy group. The authors did find a 
higher proportion of minor complications in the needle 
fasciotomy group (38% compared to 17%) but all of these 
resolved with no intervention. 
Table 1.  Tubiana Classification of Dupuytren Contracture [9, 
10] 
 
Stage 1  Combined flexion contracture of MCP and PIP joints less 
than 45 degrees 
Stage 2  Combined flexion contracture between 45 and 90 degrees 
Stage 3  Between 90 and 135 degrees 
Stage 4  Greater than 135 degrees 
 
 Badois  et al., [6] reported on a multi-centre study 
involving 952 hands in 799 patients. A total of 3736 needle 
fasciotomies were performed. An improvement in more than 
70% was achieved in 92.6% of stage 1 cases; in 77.7% of 
stage 2 cases; in 71.2% of stage 3 cases and in 56.6% of 
stage 4. Their complications were two ruptured flexor 
tendons, two nerve sections, skin cracks in 2% and 
temporary dysaesthesia in 0.8%. 
  A further study by Lermusiaux [11] involved digital 
involvement only. Thirty-two patients and 42 fingers were 
prospectively included for percutaneous needle fasciotomy. 
Three months after treatment the rate of good results was 
79%. A skin fissure was noted in one but no other adverse 
events were reported. They concluded the technique is safe 
and suitable for palmar and digital involvement. 
  A further case series assessed 90 patients and 123 hands 
for five years after one to three percutaneous fasciotomy 
sessions [6]. In total 66% of patients were followed up. The 
mean Tubiana score improved from 3.15 to 0.66. The mean 
rate of good results was 81%: 92% for Tubiana stage 1; 89% 
for stage 2; 83% for stage 3 and 48% for stage 4. At five 
years the mean Tubiana score remained low, at 0.99; the 
mean rate of good results was 69% (92% for stage 1; 74% 
for stage 2; 57% for stage 3 and 3% for stage 4). Five year 
recurrence was 50% for all cases. Adverse events included 
skin fissures in 16% and transient dysaesthesia in 2%. The 
authors noted greatest improvements were seen in the MCP 
joints (79-100% improvement), whereas PIP joints improve, 
but to a lesser extent (46-76%). 
  Three case series reported on short-term structural 
efficacy on needle fasciotomy [12-14]. Immediate or 1 week 
post treatment assessments showed 76-77% global 
improvement. There was 79-100% improvement for MCP 
joints, 46-76% for PIP joints and 75% for DIP joints. 
 
 
  The most common complications are skin fissures and 
transient nerve paraesthesias. Both generally settle down 
with little future consequence. Skin fissures may need 
regular dressings, especially if they are full thickness, and 
strenuous activities should be avoided until they heal. 
Permanent nerve injury and flexor tendon ruptures have been 
reported but are rare: Tubiana and Thomine [15] – 0.2%; 
Foucher [16] - 0.05%. 
  Recurrence is always a problem with any Dupuytren’s 
treatment and will inevitably occur over time. Van Rijssen et 
al., reported a 65% recurrence rate at average follow-up of 
32 months [14]. Bleton [17] reviewed 59 fingers with a 73 
degree average pre-operative deficit. He noted after 6 months 
that 85% of the patients did not have any MCP joint deficit, 
but 51% had a recurrent PIP deficit. 
  Percutaneous needle fasciotomy has several advantages 
over open techniques: 
•  It has lower, less serious, complication rates. 
•  Most patients recover rapidly and there are few, if 
any, restrictions after the procedure. 
•  The procedure is performed in the out-patient setting, 
under local anaesthesia. 
•  It has a similar short-term outcome and higher initial 
satisfaction among patients [8] compared to open 
procedures, especially in the case of milder 
contractures, or with contractures largely involving 
the MCP joint. 
•  In some patients it may represent a long-term 
solution. 
•  There is a significant cost saving compared to formal 
surgical procedures [18]. 
  It is not, however, a substitute for fasciectomy and formal 
surgical procedures in all cases but a useful tool in the 
reconstructive ‘ladder of treatment’ for Dupuytren’s disease. 
CONCLUSION 
  Percutaneous needle fasciotomy has been shown to be 
beneficial in Dupuytren’s disease and the short-term 
structural efficacy is well documented. It is a simple and 
quick method, with a short sick leave period for the patient, 
limited care requirements and a low overall cost. Recurrence 
rates are higher but major complications are avoided and the 
procedure can be repeated multiple times. It does not 
prohibit other treatments and may take a patient from a 
Tubiana stage 3 or 4 to a stage 2, allowing a more successful 
second stage digito-palmar fasciectomy. 
  Better results are seen at earlier stages and with more 
proximal disease. It must, however, be practised by 
experienced clinicians with an understanding of the anatomy 
and patho-anatomy of Dupuytren’s contractures to minimise 
any potential complications. 
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